I Tried Statins — Here’s What Happened | Dr Nick Norwitz MD PhD

Key wellness & self-care strategies / productivity-style takeaways

• Do your own “personalized risk-benefit” review (not one-size-fits-all)

  • Consider outcomes beyond heart health, including:
    • brain function
    • muscle integrity
    • overall well-being
  • Context matters: statins may help certain higher-risk groups, but may not be the best option for everyone.

• Recognize and monitor side effects as real data

  • Example side effects discussed: muscle pain (myalgias) and increased muscle damage markers.
  • Treat symptoms + lab signals as meaningful feedback for decision-making with a clinician.

• Support mitochondrial health if you’re concerned about statin-related mitochondrial effects

  • Statins were described as potentially impairing muscle aerobic capacity (muscle oxygen consumption recovery) and mitochondrial function, even at low concentrations in the cited study.
  • Practical supports mentioned:
    • Coenzyme Q (CoQ10), specifically a higher-bioavailability form
      • Statins were said to interfere with the body’s CoQ synthesis (an essential mitochondrial electron transporter).
      • Suggested formulation approach: Coenzyme Q phytosome (coenzyme Q + phospholipid complex) to improve absorption/bioavailability (the speaker highlights a claimed ~3× improvement vs standard CoQ).
    • Exercise focused on mitochondrial stimulation
      • The “best” mitochondrial exercise argued for: high-intensity work.
      • Suggested frequency: at least some high-intensity training ~2×/week or more.
      • Example modalities mentioned:
        • hill sprints
        • jumping alternating lunges
        • muscle-ups (if capable)
      • Framed as progressive overload—training mitochondria/metabolism, not just muscles.
    • Prioritize sleep
      • Sleep is presented as a key mitochondrial support lever (the speaker references additional content on sleep).

• Know non-statin lipid-lowering options (to reduce muscle/mitochondrial concerns)

  • The speaker is not telling viewers to switch, but recommends being aware these exist:
    • Ezetimibe
      • Mechanism: blocks intestinal cholesterol absorption (NPC1L1).
      • Positioning: described as more gut-specific, potentially less likely to harm mitochondria.
    • Bempedoic acid
      • Mechanism: liver-activated prodrug; blocks ATP citrate lyase.
      • Positioning: described as less muscle-accumulative than statins, potentially reducing muscle-related side effects/mitochondrial harm.

• Understand why certain medical findings may not reach routine practice

  • The speaker claims a structural/economic failure: follow-up studies questioning blockbuster drugs may lack funding incentives.
  • Emphasizes: peer-reviewed human data should matter, but the system may not prioritize acting on it.

Presenters / sources

• Presenter/Author: Dr. Nick Norwitz (MD PhD)
• Cited journals / studies (as referenced in subtitles):
  • Journal of Clinical Investigation(s) (atorvastatin 80 mg study; mitochondrial assays; complex IV inhibition; muscle recovery metric)
  • Cell Metabolism (previous human RCT discussed: statins and GLP-1/insulin resistance)